Clasp Therapeutics

Clasp Therapeutics is a United States-based precision immuno-oncology company headquartered in Cambridge, Massachusetts. According to its official website, the company is dedicated to "transforming the lives of patients everywhere by mastering the discovery, development and delivery of off-the-shelf precision immunotherapies." Its core technology platform is built around next-generation T cell engagers (TCEs) designed to expand the reach of immuno-oncology beyond the patients who currently benefit from existing treatments. The scientific premise of Clasp's platform is that cancer cells display mutated protein fragments, or peptides, as complexes with Human Leukocyte Antigen (HLA) molecules on their surface. These mutant peptide-HLA complexes act as a molecular fingerprint unique to the tumor, created by oncogenic mutations and presented through the cell's natural antigen presentation machinery. Because these complexes are found only on cancer cells, Clasp's T cell engagers are designed to attack with precision, sparing normal tissue and minimizing the risk of toxicity. Clasp states that by leveraging this mechanism it can access the vast majority of cancer-driving proteins that exist only inside the cell and are invisible to traditional antibody-like drugs. The company describes its approach as enabling a highly selective paradigm where every patient has the right biologic machinery to respond to treatment. Its stated focus is on tumors harboring common driver mutations, regardless of tumor type. The company is headquartered in Cambridge, Massachusetts, a major hub for biotechnology and life sciences research in the United States. Its official website presents its science and team as central elements of its identity, and it markets itself under the Clasp Therapeutics® trademark. As a privately held, early-stage biotechnology company, Clasp Therapeutics does not publicly disclose detailed financial information, and its ownership structure is not specified in the available evidence.

Clasp Therapeutics is a privately held precision immuno-oncology company based in Cambridge, Massachusetts, in the United States. The available evidence does not specify the exact year the company was founded, its founders, or its ownership structure. What is documented is its scientific mission and technology platform, which it presents through its official website. The company positions itself within the field of immuno-oncology, a therapeutic area that has produced significant results for some cancer patients, including cures, but which the company argues still has vast untapped potential for patients whose cancers do not respond to current treatments. Clasp's stated goal is to expand the reach of immuno-oncology through precision T cell engagers (TCEs) that enable the immune system to identify and specifically destroy tumors harboring common driver mutations, regardless of tumor type. The scientific foundation of Clasp's platform rests on the biology of antigen presentation. Cancer cells display mutated protein fragments, or peptides, as complexes with Human Leukocyte Antigen (HLA) molecules on their surface. These mutant peptide-HLA complexes serve as a molecular fingerprint unique to the tumor, created by oncogenic mutations and presented through the cell's natural antigen presentation machinery. By targeting these complexes, Clasp states that it can access the vast majority of cancer-driving proteins that exist only inside the cell and are invisible to traditional antibody-like drugs. Because these mutant peptide-HLA complexes are found only on cancer cells, the company's T cell engagers are designed to attack with precision, sparing normal tissue and minimizing the risk of toxicity. Clasp describes its approach as enabling a highly selective paradigm where every patient has the right biologic machinery to respond to treatment. The company is dedicated, in its own words, to transforming the lives of patients everywhere by mastering the discovery, development and delivery of off-the-shelf precision immunotherapies. Its headquarters in Cambridge, Massachusetts places it within one of the United States' leading biotechnology and life sciences clusters. As of the available evidence, Clasp Therapeutics remains an active, privately held company. No public listing, ticker symbol, or parent company is documented. Detailed corporate history, including founding date, financing rounds, and leadership appointments, is not provided in the supplied sources.

Precision immuno-oncology company developing off-the-shelf T cell engagers that target tumor-specific mutant peptide-HLA complexes to selectively destroy cancer cells while sparing normal tissue.

• Precision T cell engagers (TCEs)

  Next-generation T cell engagers designed to enable the immune system to identify and specifically destroy tumors harboring common driver mutations, regardless of tumor type, by targeting mutant peptide-HLA complexes on cancer cells.

• Off-the-shelf precision immunotherapies

  The company is dedicated to mastering the discovery, development and delivery of off-the-shelf precision immunotherapies.

1. 1Clasp Txclasptx.com
2. 2Clasp Txclasptx.com
3. 3Clasp Therapeutics (United States)wikidata.org